Rationale and Objectives
To explore the safety and efficacy of drug-eluting bead transarterial chemoembolization
(DEB-TACE) loaded with oxaliplatin for stage III-IV non-small-cell lung cancer (NSCLC).
Materials and Methods
From October 2018 to May 2021, a total of 31 patients with stage III-IV NSCLC received
DEB-TACE loaded with oxaliplatin. Demographic characteristics, adverse events (AEs),
and treatment responses were collected. Overall survival (OS) and progression-free
survival (PFS) were calculated using the Kaplan–Meier method.
Results
All 31 patients successfully received DEB-TACE loaded with oxaliplatin. No procedure-related
severe adverse events occurred. Hemoptysis symptoms presented in 8 patients but disappeared
within 1-3 days. After DEB-TACE for 1, 2, and 6 months, the objective response rate
(ORR) was 42%, 35%, and 26%, while the disease control rate (DCR) was 90%, 84% and
61%, respectively. The median PFS was 7 months (range 1-31 months), and the PFS rates
at 3, 6, and 12 months were 87%, 71% and 29%, respectively. The median OS was 11 months
(range 1-31 months), with OS rates of 87%, 77%, and 39% at 3, 6, and 12 months, respectively.
Conclusion
Oxaliplatin-loaded DEB-TACE is a feasible, safe, and effective treatment for patients
with advanced refractory non-small-cell lung cancer.
Key Words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Academic RadiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
REFERENCES
- Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment.Mayo Clin Proc. 2019; 94: 1623-1640
- The efficacy of drug-eluting beads bronchial arterial chemoembolization loaded with gemcitabine for treatment of non-small cell lung cancer.Thorac Cancer. 2019; 10: 1770-1778
- Drug-eluting beads bronchial arterial chemoembolization in treating relapsed/refractory small cell lung cancer patients: results from a pilot study.Cancer Manag Res. 2021; 13: 6239-6248
- NCCN guidelines insights: non–small cell lung cancer, version 1.2020.J Natl Compr Canc Netw. 2019; 17: 1464-1472
- Real-world treatment patterns, overall survival, and occurrence and costs of adverse events associated with first-line therapies for medicare patients 65 years and older with advanced non–small-cell lung cancer: a retrospective study.Clinical Lung Cancer. 2018; 19: e629-e645
- Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence.Cancer Treat Rev. 2019; 72: 28-36
- DEB-TACE: a standard review.Future Oncol. 2018; 14: 2969-2984
- Oral bioavailability and first-pass effects.Drug Metab Dispos. 1997; 25: 1329-1336
- Clinical outcomes of doxorubicin-eluting CalliSpheres® beads-transarterial chemoembolization for unresectable or recurrent esophageal carcinoma.BMC Gastroenterology. 2021; 21: 231
- Clinical outcomes of uterine arterial chemoembolization with drug-eluting beads for advanced-stage or recurrent cervical cancer.Abdom Radiol(NY). 2021; 46(12): 5715-5722
- Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish lung cancer study group.J Clin Oncol. 2005; 23: 8380-8388
- Chemotherapy for advanced-stage non-small cell lung cancer.Cancer J. 2015; 21: 366-370
- A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer.Br J Cancer. 2013; 108: 265-270
- Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer.Lung Cancer. 2012; 77: 104-109
- Tumor response assessment by measuring the single largest lesion per organ in patients with advanced non-small cell lung cancer.Lung Cancer. 2014; 85: 385-389
- Drug-eluting beads bronchial arterial chemoembolization as a neoadjuvant treatment for squamous non-small cell lung cancer.Postgrad Med. 2020; 132: 568-571
- Drug-eluting beads bronchial arterial chemoembolization plus intercostals arterial infusion chemotherapy is effective and well- tolerated in treating non-small cell lung cancer patients with refractory malignant pleural effusion.J Thorac Dis. 2021; 13: 2339-2350
- Management of hemoptysis in patients with lung cancer.Ann Transl Med. 2019; 7: 358
- Intra-arterial embolotherapy for intrahepatic cholangiocarcinoma: update and future prospects.Hepatobiliary Surg Nutr. 2017; 6: 7-21
- Bronchial artery embolization for hemoptysis in primary lung cancer: a retrospective review of 84 patients.J Vasc Interv Radiol. 2019; 30: 428-434
- Immediate and late outcomes of bronchial and systemic artery embolization for palliative treatment of patients with nonsmall-cell lung cancer having hemoptysis.Am J Hosp Palliat Care. 2014; 31: 602
- Quantification of perfusion reduction by using 2D-perfusion angiography following transarterial chemoembolization with drug-eluting beads.Abdom Radiol (NY). 2018; 43: 1245-1253
- Commentary on: evaluation of a newly developed 2D parametric parenchymal blood flow technique with an automated vessel suppression algorithm in patients with chronic thromboembolic pulmonary hypertension undergoing balloon pulmonary angioplasty.Clin Radiol. 2019; 74: 435-436
Article info
Publication history
Published online: February 14, 2022
Accepted:
January 18,
2022
Received in revised form:
January 17,
2022
Received:
November 28,
2021
Identification
Copyright
© 2022 The Association of University Radiologists. Published by Elsevier Inc. All rights reserved.
